Amgen bets on growth in China

Biotechnology company Amgen is investing U.S. $2.7 billion in the Chinese biotech firm Beigene. The all-cash deal values gives Amgen a 20% stake in BeiGene and going forward, BeiGene will commercialize some of Amgen’s cancer drugs which will be sold in China. The two...

Join Us & Stay Informed!

* indicates required

Your Preferences   (Please select all the ways you would like to hear from)

You are a *

Confirm *